Elevated Zero Maze
Latency to first open quadrant entry, time in open, and number of head dips were analyzed. For latency, there was a main effect of drug, F(1,49) = 4.5, p< 0.04; the MA-treated groups had decreased latency to first open entry compared to the SAL-treated groups (). There were no main effects or interactions on time in open or head dips.
Locomotor Activity
Total, central, and peripheral distances, horizontal activity, and vertical activity were analyzed. For total distance, there were no surgery × treatment × day interactions, (), but there were main effects of drug, F(1,72.8) = 5.1, p< 0.03, time, F(11,674) = 92.5, p< 0.0001, and interactions of surgery × time, F(11,674) = 1.9, p< 0.04, and drug × time, F(11,674) = 2.3, p< 0.01. MA-treated groups were hypoactive compared to SAL-treated groups ( inset). Further analysis of the drug × time interaction revealed that the MA-treated groups had reduced locomotion from 10-20 min and at 55 min compared to SAL-treated groups (). Similar results were obtained for horizontal activity. For peripheral distance, there were main effects of drug, F(1,72.8) = 10.4, p< 0.002, time, F(11,679) = 65.2, p< 0.0001, and interactions of surgery × time, F(11,679) = 2.1, p< 0.02, and drug × time, F(11,679) = 4.2, p< 0.0001. MA-treated groups moved less in the periphery than did SAL-treated groups (not shown). The drug × time interaction showed decreased peripheral distance in MA-treated groups from 10-20 and 50-55 min compared to SAL-treated groups (not shown). For center distance, an overall effect of time was observed, F(11,658) = 83.5, p< 0.001, but no treatment-related effects were seen. For vertical activity, there were main effects of drug, F(1,55.9) = 11.24, p< 0.001, and time, F(11,679) = 3.5, p< 0.0001. MA-treated groups had increased vertical movements compared to SAL-treated groups (not shown).
Morris Water Maze Hidden Platform
Spatial learning in the MWM was analyzed for path length, latency to the target platform, cumulative distance, and mean speed. For acquisition path length (), there were main effects of drug, F(1,54.7) = 8.6, p< 0.005, and day, F(4,201) = 97.2, p< 0.0001, and the interaction of drug × day, F(4,201) = 3.5, p< 0.01. Further analysis of the interaction showed that on days 1 and 2, MA-treated groups had increased path length compared to SAL-treated groups, regardless of surgery (). Similar findings were observed for latency and cumulative distance (not shown). For swim speed, there were main effects of drug, F(1,55.7) = 4.5, p< 0.04, and day, F(4,212) = 4.4, p< 0.002. MA-treated groups swam slower compared to SAL-treated groups (not shown). There were no other significant effects.
For reversal path length (), there were main effects of drug, F(1,74) = 8.6, p< 0.005, and day, F(4,220) = 66.9, p< 0.0001, and a drug × day interaction, F(4,220) = 2.8, p< 0.03. The interaction was attributable to increased path length in MA-treated groups on days 1 and 2 (). Analyses of latency and cumulative distance were similar. For swim speed, the only main effect was day, F(4,210) = 13.0, p< 0.0001.
For shift path length (), there were main effects of drug, F(1,53.3) = 9.5, p< 0.003 (), and day, F(4,204) = 66.7, p<0.0001, but no interactions. The MA-treated animals had longer path lengths than the SAL-treated animals, regardless of surgery. Similar findings were observed for latency and cumulative distance. For speed the only main effect was for day, F(4,214) = 12.3, p< 0.0001.
For probe trials, platform site crossovers, initial heading error, and average distance from the target were analyzed. For acquisition probe initial heading error, there was a main effect of drug, F(1,53) = 10.7, p< 0.002, which was attributable to increased heading error in MA-treated groups compared to SAL-treated groups (). There were no effects for crossovers or average distance.
For reversal probe crossovers, there was a main effect of surgery, F(1,53) = 6.0, p< 0.02. For initial heading error, there was a main effect of drug, F(1,53) = 4.6, p< 0.04. SHAM groups had fewer crossovers than the ADXA groups (not shown) and MA-treated groups had increased initial heading errors than SAL-treated groups ().
For shift probe initial heading error, there was a main effect of drug, F(1,53) = 18.6, p< 0.0001, in which MA-treated groups had greater heading errors than SAL-treated groups (). There were no effects for average distance from the target on acquisition, reversal, or shift probe trials.
Morris Water Maze Cued
There was a latency main effect of day, F(1,71) = 29.6, p< 0.0001, but no effects of drug, surgery, or interactions.
Corticosterone
Corticosterone levels were measured following 10 min forced swim in adulthood to determine the extent of which ADXA attenuated CORT release. There was an overall effect of surgery, F(1,45) = 17.7, p< 0.001, in which the ADXA groups had plasma CORT levels that were significantly lower than SHAM groups (). CORT levels were 50.2% of their respective controls (). There were no effects of drug or interactions.
Monoamines
Monoamines were analyzed in the hippocampus, neostriatum, and entorhinal cortex (). In the hippocampus (), there was a main effect of drug for 5-HIAA, F(1,40) = 5.1, p< 0.03, and a surgery × drug interaction for NE, F(1,40) = 4.0, p< 0.05. 5-HIAA was decreased in the MA-treated groups compared to SAL-treated groups () and NE was increased in the ADXA-MA group () compared to the ADXA-SAL group. For neostriatal 5-HT (), there was a main effect of drug, F(1,39) = 2.6, p< 0.05, in which the MA-treated groups had reduced 5-HT compared to the SAL-treated groups (). No neonatal surgery × drug interactions were observed. In the entorhinal cortex (), there were main effects of drug for both 5-HT, F(1,39) = 5.7, p< 0.02, and 5-HIAA levels, F(1,38) = 4.6, p< 0.04. 5-HT and 5-HIAA levels were reduced in the MA-treated groups compared to the SAL-treated groups ().